EmaxHealth Health News
Home » Personal Health » Prescription Drugs

Eli Lilly Program To Help States Monitor Psychiatric Prescriptions Examined

Ads by Google

All About:
  • Prescription Drugs

By Armen Hareyan on August 21, 2007 - 11:55am for eMaxHealth

A program sponsored by Eli Lilly has helped Medicaid programs in Minnesota and other states monitor prescriptions for psychiatric medications, the St. Paul Pioneer Pressreports. According to Minnesota officials, the program has helped thestate reduce costs and prevent unnecessary prescriptions forpsychiatric medications, but critics have raised concerns because thecompany has a financial interest in state policies that promote salesof such treatments (Olson, St. Paul Pioneer Press, 8/20).

Under the program, which Lilly launched in 2003, the company pays Comprehensive NeuroSciencean undisclosed amount to help state Medicaid programs monitorprescriptions for psychiatric medications. In the event that physiciansoverprescribe psychiatric medications to Medicaid beneficiaries, CNSsends "Dear Doctor" letters to inform them of the issue. Physicians donot have to comply with the letters. CNS also notifies physicians whenMedicaid beneficiaries do not renew their prescriptions for psychiatricmedications (Kaiser Daily Health Policy Report, 3/23).

Lillydoes not charge states that participate in the program. However,critics have raised concerns that "states are paying Lilly back forthis help by keeping its drugs off prior authorization lists," whichinclude medications that physicians cannot prescribe to Medicaidbeneficiaries without permission from the state, the Pioneer Press reports. None of the states that participate in the program has prior authorization lists for psychiatric medications (St. Paul Pioneer Press,8/20). Lilly manufactures Zyprexa, a treatment for schizophrenia andbipolar disorder that accounts for the single largest medicationexpenditure for state Medicaid programs (Kaiser Daily Health Policy Report, 3/23).

Lilly Response

Lilly spokesperson Janice Chavers acknowledged that the company seeksto discourage the use of prior authorization lists. She said, "We justfeel the doctor should be in the driver's seat as far as picking thebest medication, especially an antipsychotic" (St. Paul Pioneer Press, 8/20).

Reprinted with permission from kaisernetwork.org. Youcan view the entire Kaiser DailyHealth Policy Report, search the archives, and sign up for email deliveryat kaisernetwork.org/email. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, afree service of The Henry J. Kaiser Family Foundation.

Source: 
Kaisernetwork.org

eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.

  • Add new comment

Similar Stories

  • Vertex Kalydeco for Cystic Fibrosis Approved by FDA Ahead of Schedule
  • Israeli researchers discover method to fight superbugs
  • FDA proposal would accelerate approval of generic drugs
  • Pradaxa vs. Warfarin: Should Cardiac Patients Worry?
  • Novartis Recalls Excedrin, NoDoz: What’s In Your Bottle?

 Dr. Oz Promotes Magnet Cure
 Skin Care Secrets in Your Kitchen
 3 Gadgets to Make You Look 10 Years Younger
 Catalase is the Culprit for Gray Hair
 Vibration Therapy Helps Chronic Pain
 What If Antidepressants Don't Work
 When Obesity is OK for Some

Health Categories

 EMAXHEALTH HOME
 AFFORDABLE HEALTH INSURANCE
 DIET & WEIGHT LOSS
 FITNESS & EXERCISE
 MEN'S HEALTH
 WOMEN'S HEALTH
 BEAUTY
 ALTERNATIVE MEDICINE
 CANCER TREATMENT
 AGING
 DISEASE and CONDITION
 MENTAL HEALTH
 GENERAL HEALTH
 PERSONAL HEALTH
 GOURMET FOOD & HEALTH
 HEALING & SPIRITUALITY
 MONEY AND HEALTH
 Comment Moderation
  • Health RSS Feeds
  • Privacy Policy
  • Disclaimer
  • About Us
  • Editorial Review Process
  • Advertise
  • Contact
  • Contributors
Copyright eMaxhealth.com 2005-2012. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.